Current Issues With the Use of Bedaquiline

Annals of Pharmacotherapy

Volumn 48, Issue 5, 2014, Pages 666-

  Kakkar, Ashish Kumar ^a   Dahiya, Neha ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BEDAQUILINE;

CLINICAL PHARMACOLOGY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ANIMALS; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84898687717     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014521589     Document Type: Letter

References (4)

1. Chahine EB,Karaoui LR,Mansour H.Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.Ann Pharmacother.:.
2. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, Switzerland: World Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf. Accessed January 11, 2013.
3. MarshallH. New drug approved for MDR tuberculosis, despite concerns. Lancet. 2013. http://download.thelancet.com/flatcontentassets/lanres/edch/140113_2_1.pdf. Accessed January 11, 2013.
4. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.MMWR Recomm Rep. 2013;62 (RR-09): 1-12.